155. INTER-INSTITUTIONAL SURVIVAL HETEROGENEITY BETWEEN SURGERY AND CHEMORADIOTHERAPY FOR CLINICAL STAGE I ESOPHAGEAL CANCER: EXPLORATORY ANALYSIS OF JCOG0502
Rattachement africain : us, jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Surgery and chemoradiotherapy (CRT) are treatment options for clinical stage I esophageal squamous cell carcinoma (ESCC). However, the distribution of these treatments varies among institutions, potentially contributing to differences in outcomes between high- and low-volume centers. JCOG0502, a parallel-group controlled trial, showed comparable efficacy between surgery and CRT for stage I ESCC, though institutional preferences may have influenced the patient’s treatment selection. While previous reports suggest physician recommendations impact patient decision-making, variations in outcomes and adverse events (AEs) between institutions remain insufficiently explored. Methods Of the 379 cases enrolled in JCOG0502, 364 were analyzed, excluding 15 cases due to ineligibility or non-protocol treatments. Institutions that enrolled ≥5 cases were categorized as high-enrollment centers (High), while those with <5 were classified as low-enrollment centers (Low). The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), AEs, and surgical complications. Results A total of 202 cases (n = 186: High, n = 16: Low) in the surgery group and 162 cases (n = 150: High, n = 12: Low) in the CRT group were analyzed. The 5-year PFS (High vs. Low) was 81% vs. 93% in the surgery group (p = 0.23) and 71% vs. 66% in the CRT group (p = 0.91). The 5-year OS (High vs. Low) was 87% vs. 93% in the surgery group (p = 0.44) and 85% vs. 92% in the CRT group (p = 1.00). ≥ Grade 3 neutropenia and myocardial ischemia in Low was significantly higher than in High in the CRT group (33% vs. 9%, 17% vs. 2%, p < 0.05). Conclusion In stage I ESCC, no significant difference in survival outcomes was observed between the high-enrollment and low-enrollment centers in either the surgery or CRT groups. Several AEs of early and late phase in CRT were significantly different between high-enrollment and low-enrollment centers. However, due to the imbalance in case numbers, caution is required when interpreting these results.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- 155. INTER-INSTITUTIONAL SURVIVAL HETEROGENEITY BETWEEN SURGERY AND CHEMORADIOTHERAPY FOR CLINICAL STAGE I ESOPHAGEAL CANCER: EXPLORATORY ANALYSIS OF JCOG0502
- Date Crossref
- 01/08/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Cancer Center pays non établi dans la noticeOrganisation à but non lucratif
-
Nagoya Medical Center pays non établi dans la noticeÉtablissement de santé
-
Tokyo National Hospital pays non établi dans la noticeÉtablissement de santé
-
SHOWA Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Shikoku Cancer Center pays non établi dans la noticeÉtablissement de santé
-
National Cancer Center Hospital East pays non établi dans la noticeÉtablissement de santé
-
Osaka International Cancer Institute pays non établi dans la noticeÉtablissement de santé
-
Toranomon Hospital pays non établi dans la noticeÉtablissement de santé
-
Niigata Cancer Center Hospital pays non établi dans la noticeÉtablissement de santé
-
Shizuoka General Hospital pays non établi dans la noticeÉtablissement de santé
-
Kyoto University pays non établi dans la noticeUniversité ou école supérieure
-
Aichi Cancer Center pays non établi dans la noticeÉtablissement de santé
National Cancer Center, Nagoya Medical Center et Tokyo National Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.